Aortic Stenosis, Heart Failure, and Aortic Valve Replacement
JAMA Cardiology
OCTOBER 15, 2024
This narrative review analyzes associations among heart failure, aortic stenosis, and aortic valve replacement.
This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
JAMA Cardiology
OCTOBER 15, 2024
This narrative review analyzes associations among heart failure, aortic stenosis, and aortic valve replacement.
DAIC
MARCH 25, 2024
The global, randomized trial ( envisiontrial.com ) will evaluate the safety and effectiveness of Abbott’s minimally invasive Navitor transcatheter aortic valve implantation (TAVI) system in approximately 1,500 patients at intermediate or low surgical risk with severe aortic stenosis (narrowing of the aortic valve).
DAIC
APRIL 25, 2024
Aortic stenosis is a narrowing of the aortic valve which prevents the aortic leaflets from opening and closing properly. Patients with aortic stenosis often have heart murmurs and experience debilitating symptoms including chest pain, dizziness, fatigue, shortness of breath and an irregular heartbeat.
DAIC
MARCH 28, 2024
milla1cf Thu, 03/28/2024 - 07:30 March 28, 2024 — Medtronic plc, a global leader in healthcare technology, announced that the United States Food and Drug Administration ( FDA ) has approved the Evolut FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. Circulation.
JAMA Cardiology
APRIL 5, 2024
This cohort study explores whether a novel artificial intelligence (AI) video-based biomarker for aortic stenosis is associated with development and progression of aortic stenosis.
HCPLive
OCTOBER 11, 2024
be overtreating aortic stenosis. Linda Gillam, MD, MPH, discusses the idea that the cardiology community may.
JAMA Cardiology
JULY 16, 2024
This meta-analysis evaluates lipoprotein(a) concentrations and hemodynamic progression in patients with aortic stenosis.
Med Page Today
OCTOBER 28, 2024
(MedPage Today) -- Transcatheter aortic valve replacement (TAVR) yielded clinical benefit when given early in the disease process while patients still had no symptoms or other indication for aortic valve replacement, according to the EARLY TAVR.
American College of Cardiology
MAY 24, 2024
What is the relationship between aortic valve calcification (AVC) and aortic stenosis (AS) severity in patients with suspected low-flow low-gradient AS?
American College of Cardiology
FEBRUARY 21, 2024
Echocardiography remains the principal imaging modality for detection and diagnosis of aortic stenosis (AS), as well as for grading of severity.
Open Heart
JANUARY 8, 2024
Background A quarter of patients with severe aortic stenosis (AS) were asymptomatic, and only a third of them survived at the end of 4 years. Only a select subset of these patients was recommended for aortic valve replacement (AVR) by the current American College of Cardiology/American Heart Association guidelines.
Cardiology Update
FEBRUARY 11, 2024
The NOTION trial, a pioneering study, sought to compare the long-term clinical and bioprosthesis outcomes of Transcatheter Aortic Valve Implantation (TAVI) versus Surgical Aortic Valve Replacement (SAVR) in patients with severe aortic valve stenosis (AS) at lower surgical risk. Severe SVD was defined by specific criteria.
American College of Cardiology
SEPTEMBER 18, 2024
The goal of the AVATAR trial was to evaluate aortic valve replacement (AVR) compared with conservative therapy among patients with asymptomatic severe aortic stenosis.
Medical Xpress - Cardiology
OCTOBER 29, 2024
Until now, patients with aortic stenosis—a narrowing of one of the heart's main valves—have had to wait until symptoms become severe before undergoing valve replacement.
Frontiers in Cardiovascular Medicine
FEBRUARY 23, 2024
This concept should be applied when managing older patients with severe aortic stenosis. Although left ventricular wall hypertrophy is expected in patients with aortic stenosis, it should not be assumed that this is caused only by aortic stenosis.
American College of Cardiology
MARCH 6, 2024
What are the hemodynamic and clinical outcomes after transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) among patients with severe aortic stenosis (AS) and a small aortic annulus?
American College of Cardiology
OCTOBER 28, 2024
The goal of the EARLY TAVR trial was to evaluate transcatheter aortic valve replacement (TAVR) compared with clinical surveillance among patients with asymptomatic severe aortic stenosis (stage C aortic stenosis).
American College of Cardiology
SEPTEMBER 27, 2024
How does diffuse interstitial myocardial fibrosis, as observed on cardiac magnetic resonance (CMR), correlate with clinical outcomes in moderate and asymptomatic severe aortic stenosis (AS)?
American College of Cardiology
MAY 29, 2024
In this week’s View, Dr. Eagle looks at the diagnostic value of aortic valve calcification levels in the assessment of low-gradient aortic stenosis.
Heart BMJ
JULY 10, 2024
Valvular heart disease, including calcific or degenerative aortic stenosis (AS), is increasingly prevalent among the older adult population. Over the last few decades, treatment of severe AS has been revolutionised following the development of transcatheter aortic valve replacement (TAVR).
DAIC
APRIL 25, 2024
Aortic stenosis is a narrowing of the aortic valve which prevents the aortic leaflets from opening and closing properly. Patients with aortic stenosis often have heart murmurs and experience debilitating symptoms including chest pain, dizziness, fatigue, shortness of breath and an irregular heartbeat.
JAMA Cardiology
NOVEMBER 5, 2024
This genomewide association study examined specific genetic variants, pathways, and tissues associated with aortic stenosis independent of coronary artery disease in a meta-analysis of participants from 3 European cohorts.
Frontiers in Cardiovascular Medicine
AUGUST 7, 2024
Aortic Stenosis (AS) is a common condition with an estimated pooled prevalence of all AS in the elderly population at around 12.4%, with that of severe AS estimated to be around 3.4%. In the past, surgical aortic valve replacement was the primary treatment option for severe AS for decades.
American College of Cardiology
JULY 23, 2024
What is the association between plasma lipoprotein(a) [Lp(a)] concentrations and hemodynamic progression in patients with aortic stenosis?
DAIC
JANUARY 29, 2024
Getty Images milla1cf Mon, 01/29/2024 - 14:24 January 29, 2024 — Despite national guidelines recommending surgical aortic valve replacement (SAVR) for patients under age 65 with severe aortic stenosis , many hospitals are still opting for a nonsurgical approach in patients under 60—possibly with poorer survival rates.
American College of Cardiology
APRIL 22, 2024
What is the 5-year incidence of valve reintervention after self-expanding CoreValve/Evolut transcatheter aortic valve replacement (TAVR) versus surgical aortic valve replacement (SAVR)?
American College of Cardiology
JUNE 18, 2024
In this week's View, Dr. Eagle looks at secular trends of incidence and outcomes in severe aortic stenosis. He then examines titration of medications after acute heart failure.
American College of Cardiology
APRIL 8, 2024
The goal of the DEDICATE-DZHK6 trial was to evaluate transcatheter aortic valve implantation (TAVI) compared with surgical aortic valve replacement (SAVR) among patients with severe aortic stenosis and low to intermediate surgical risk.
Science Daily - Heart Disease
NOVEMBER 26, 2024
A large new population study of men over 45 indicates insulin resistance may be an important risk factor for the development of the world's most common heart valve disease -- aortic stenosis (AS).
American College of Cardiology
NOVEMBER 20, 2024
Which genetic and cardiovascular risk factors are aortic stenosis (AS)-specific, and which could be shared between AS and with coronary artery disease (CAD)?
DAIC
DECEMBER 26, 2023
reported results from a clinical study of revolutionary earbuds that use a new technology - In-ear Infrasonic Hemodynography to Detects Aortic Stenosis Murmur Before and After Transcatheter Aortic Valve Replacement (TAVR). milla1cf Tue, 12/26/2023 - 21:36 December 26, 2023 — MindMics, Inc. the R&D Manager of MindMics.
American College of Cardiology
SEPTEMBER 24, 2024
What are the clinical features and prognosis of patients with high-gradient (HG) aortic stenosis (AS) with a calculated aortic valve area (AVA) of >1.0
American College of Cardiology
JANUARY 16, 2024
In this review, authors discuss how multimodality imaging can help to evaluate the left ventricular remodeling response and improve risk stratification in patients with moderate aortic stenosis.
American College of Cardiology
DECEMBER 17, 2024
The following are key points to remember from a review on aortic stenosis (AS), heart failure (HF), and aortic valve replacement (AVR).
American College of Cardiology
APRIL 4, 2024
The goal of the VIVA trial was to evaluate transcatheter aortic valve replacement (TAVR) compared with surgical aortic valve replacement (SAVR) among patients with severe aortic stenosis and a small aortic annulus.
American College of Cardiology
JUNE 7, 2024
A novel interactive, online decision aid used at the point of care among patients with severe aortic stenosis (AS) was strongly endorsed by patients and clinicians, easy to use and improved the quality of shared decision-making with a treatment decision that reflected patient values.
Open Heart
FEBRUARY 27, 2024
Objectives The clinical outcomes of transcatheter aortic valve replacement (TAVR) in patients with aortic stenosis (AS) and concomitant active cancer remain insufficiently explored. This study aimed to assess the midterm outcomes of TAVR in patients diagnosed with AS and active cancer.
Journal of Cardiothoracic Surgery
APRIL 19, 2024
Patients with severe aortic stenosis (AS) and left ventricular (LV) dysfunction demonstrate improvement in left ventricular injection fraction (LVEF) after aortic valve replacement (AVR). The timing and magnit.
Journal of Cardiothoracic Surgery
FEBRUARY 3, 2024
Anomalous aortic origin of the coronary artery (AAOCA) is a rare congenital heart disease. Therefore, optimal indications for surgery in patients with severe aortic valve stenosis (AS) complicated by AAOCA rem.
Medical Xpress - Cardiology
SEPTEMBER 3, 2024
Transcatheter aortic valve implantation (TAVI) was superior to surgical aortic valve replacement for reducing death, stroke or rehospitalization in women with severe aortic stenosis, according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.
Frontiers in Cardiovascular Medicine
APRIL 24, 2024
With this longer lifespan, calcific aortic stenosis (AS) was identified as an emerging critical risk factor for cardiac death in older patients. Modified transcatheter aortic valve replacement (TAVR) and left ventricular Apico-Aortic Conduit (AAC) placement were deemed high risk but viable options. years by 4.3
Heart BMJ
APRIL 15, 2024
Objective Aortic stenosis (AS) shares pathophysiological similarities with atherosclerosis including active inflammation. CT attenuation of perivascular adipose tissue provides a measure of vascular inflammation that is linked to prognosis and has the potential to be applied to the aortic valve. HU, p=0.099).
Journal of Cardiothoracic Surgery
FEBRUARY 13, 2024
Rapid-deployment aortic valve replacement (RDAVR) is an alternative to conventional AVR (cAVR) for aortic stenosis. Benefits include a reduction in operative times, facilitation of minimal access surgery and s.
HCPLive
OCTOBER 13, 2024
Linda Gillam, MD, MPH, discusses updates in the management of aortic stenosis, with a focus on use of TAVR.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content